Clinical Trial Update: Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Ramosetron, Aprepitant, and Dexamethasone (RAD) in solid tumors, including cancer indications and postoperative nausea and vomi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Nausea and Vomiting
• Solid Tumor

Drugs mentioned

• Decadron (Dexamethasone)
• EMEND (aprepitant)
• Ramosetron (ramosetron)

Snippet

Sponsor: Hallym University Medical Center | Conditions: Solid Tumour, Postoperative Nausea and Vomiting | Phase 2 | Status: UNKNOWN